Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

(2014) Gillian M. Keating   DRUGS

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment

(2011) E. Ritz   DIABETES CARE

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

(2011) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

(2011) Midori Ito et al.   ENDOCRINE JOURNAL

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States

(2011) Ian H. de Boer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

(2010) M. Ligueros-Saylan et al.   DIABETES OBESITY & METABOLISM

Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals

(2010) JosephA Davis et al.   INDIAN JOURNAL OF PHARMACOLOGY

Diabète et maladie rénale chronique : ce que nous apprend l’épidémiologie

(2010) Emmanuel Villar et al.   Nephrologie & Therapeutique

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

(2009) Raffaele Marfella et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM